非小细胞肺癌患者血清中IL-10水平的临床意义  

Serum IL-10 levels as diagnostic and prognostic factors in advanced non-small cell lung cancer patients

作　　者：张妍蓓[1] 刘荣玉[1] 汪伟民[1] 孙昕[2] 赵卉[1] 庞玉瑛[1] 

机构地区：[1]安徽医科大学附第一属医院呼吸内科,合肥230022 [2]安徽医科大学附第一属医院实验中心,合肥230022

出　　处：《安徽医科大学学报》2003年第2期127-129,共3页Acta Universitatis Medicinalis Anhui

基　　金：安徽省教育厅科研基金资助课题(编号:2 0 0 3KG2 0 4 )

摘　　要：目的　探讨非小细胞肺癌 (NSCLC)患者血清中IL 1 0的水平在肿瘤发生、发展、转移和预后中的作用及其临床意义。方法　选择TNM分期为Ⅲ～Ⅳ期的NSCLC患者 44例 ,其中 30例接受以铂类药为主的化疗 ;另选 30例健康成人作为对照组。在治疗前及治疗后 1个月应用ELISA测定血清IL 1 0水平。结果　所有患者血清中的IL 1 0水平 (ng/L)均高于健康对照组 (1 92 37± 1 3 46vs 84 2 0± 2 1 7,P<0 0 1 ) ;Ⅳ期的NSCLC患者血清IL 1 0水平 (ng/L)高于Ⅲ期NSCLC患者 (2 68 2 7± 2 5 0 3vs 1 51 1 6± 1 0 2 0 ,P <0 0 1 )。 1个疗程后 1个月有 1 8例病情稳定或肿瘤部分缩小 ,1 2例治疗无效。治疗有效者的血清IL 1 0水平 (ng/L)降低 (2 0 8 1 8± 2 0 0 5vs 1 2 9 96± 1 4 2 2 ,P <0 0 5) ;治疗无效者的血清IL 1 0水平 (ng/L)略低于治疗前 (1 75 54± 1 3 60vs 1 62 1 3± 1 1 69,P >0 0 5)。结论　血清IL 1 0水平与NSCLC的发生及其转移相关 ,提示IL 1 0在NSCLC的发生和发展中起着某种重要的作用 ,测定血清IL 1Objective To investigate the prognostic signi ficance of interleukin(IL-10) serum levels in advanced non-small cell lung cancer (NSCLC) patients. Methods IL-10 serum levels were measured before chemotherapy and on completion of therapy, by means of a commercially available enzyme-linked immunoassay. The results were then analyzed in comparison with other prognostic variables. The study used 44 patients with TNM stage Ⅲ or Ⅳ NSCLC undergoing conventional platinum-based treatment. Results Elevated levels of serum IL-10(ng/L) were found in cancer patients compared with healthy control subjects (192 37±13 46 vs 84 20±2 17 , P<0 01). Patients of metastatic disease showed significantly higher levels of serum IL-10(ng/L) than patients with undis seminated cancer (268 27±25 03 vs 151 16±10 20, P<0 01). Following completion of treatment, patients were classified as responders if they had achieved either one of the following: complete response, partial response, or stable disease; and nonresponders, in case of progressive disease. Decrease in IL -10 serum levels (ng/L) was observed in nonresponders prechemotherapy and at t he end of therapy (175 54±13 60 vs 162 13±11 69, P>0 05) and in responders (208 18±20 05 vs 129 96±14 22, P<0 05). Conclusion In conclusion, this study shows that the measu rement of pretreatment IL-10 serum levels is a reliable, sensitive and easy method and is of independent prognostic utility in patients with NSCLC and may be useful for pre dicting disease progression.

关 键 词：非小细胞肺癌 血清 IL-10 白细胞介素lO 预后 肿瘤发生 肿瘤发展 肿瘤转移 测定 

分 类 号：R734.2[医药卫生—肿瘤] R446.112[医药卫生—临床医学]